UD 005 Clinical questions to be addressed: Biologic subtypes of breast cancer determine response to different chemotherapeutic agents. Targeted biologic therapies improve progression-free but not overall survival for patients with advanced breast cancer. EGFR inhibitors improve efficacy of chemotherapy for patients with advanced colorectal cancer. Inhibitors of vascular endothelial growth factor receptor have activity against metastatic renal cell carcinoma. PET scans after initial treatment improve our prognostic ability for patients with Hodgkin's lymphoma. Changing epidemiology of breast cancer in relation to hormone replacement therapy.